港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

医药外包概念

2,461.148

+78.8533.31%

涨家数：6

跌家数：2

平家数：- -

市盈率：- -

高：2,534.056

开：2,382.859

低：2,375.883

收：2,382.295

数据加载中...

和誉-B附属和誉医药完成创新PRMT5*MTA抑制剂ABSK131的 1期临床试验首例患者给药

智通财经网

丽珠医药抗癫痫1类新药NS-041完成Ⅱ期临床试验首例患者给药

中证健康产业指数上涨1.03%，前十大权重包含药明康德等

易方达基金增持泰格医药(03347)37万股每股作价约49.98港元

狂砍500亿订单，医药大白马，未来10年无悬念！

远大医药(00512)：全球创新放射性核素偶联药物TLX591加入国际多中心III期临床试验的申请获中国药监局默示许可

智通财经网

药明生物五个生产厂通过美国FDA上市批准前检查，商业化预充针灌装厂首获批准

药明康德(02359)7月22日斥资2699.38万元回购A股32.32万股

每日卖空追踪 | 康龙化成 07月22日卖空量成交21.68万股，卖空比例为2.27%

每日卖空追踪 | 泰格医药 07月22日卖空量成交9.95万股，卖空比例为1.89%

每日卖空追踪 | 药明康德 07月22日卖空量成交83.47万股，卖空比例为11.96%

湘财证券：ADC到XDC 偶联药物CDMO空间广阔

方达控股盘中异动下午盘大幅上涨5.19%报1.420港元

昭衍新药盘中异动下午盘快速跳水5.12%报20.400港元

恒瑞医药宣布重磅减肥创新药 Ⅲ 期临床试验获得积极顶线结果

港股异动丨金斯瑞生物科技涨超8%，预计上半年扭亏为盈最多录得逾2亿美元利润

老虎资讯综合

【港股医药股多数走强博安生物涨超8%】截至发稿，博安生物(06955.HK)涨8.33%、金斯瑞生物科技(01548.HK)涨7.19%、再鼎医药(09688.HK)涨6.76%、来凯生物-B(02105.HK)涨5.57%。

口服多肽向FDA递交上市申请药明康德共同强生等参与

港股异动 | 丽珠医药涨超9%，LZM012 Ⅲ期临床试验达主要研究终点

金斯瑞生物科技盘中异动早盘急速上涨5.12%报17.260港元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK1576/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"医药外包概念","latestPrice":2461.148,"timestamp":1753430886160,"preClose":2382.2947,"halted":0,"volume":202568720,"delay":0,"changeRate":0.0331,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":78.853271,"latestTime":"07-25 16:00:00","open":2382.8591,"high":2534.0562,"low":2375.8826,"amount":6024679434.2,"amplitude":0.066395,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753666200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1753407000000,1753416000000],[1753419600000,1753430400000]],"pbRate":2.905027,"peRate":13.881935,"turnoverRate":0.017592,"increases":6,"decrements":2,"flats":0,"marketCap":558178889472,"floatMarketCap":227049556480},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":2534.0562,"amplitude":0.066395,"preClose":2382.2947,"low":2375.8826,"pbRate":"2.905027","latestPrice":2461.148,"volume":202568720,"delay":0,"open":2382.8591,"prevYearClose":1395.7731,"prevWeekClose":2262.402,"prevMonthClose":1988.255,"prevQuarterClose":1988.255,"fiveDayClose":2262.402,"twentyDayClose":1938.457,"sixtyDayClose":1672.916,"secType":"PLATE","market":"HK","turnoverRate":0.017592,"peRate":13.881935,"marketCap":558178889472,"floatMarketCap":227049556480,"timestamp":1753430886160,"nameCN":"医药外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":6,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2553261134","title":"和誉-B附属和誉医药完成创新PRMT5*MTA抑制剂ABSK131的 1期临床试验首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2553261134","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553261134?lang=zh_cn&edition=fundamental","pubTime":"2025-07-23 08:05","pubTimestamp":1753229134,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，公司的附属公司上海和誉生物医药科技有限公司(和誉医药)宣布，其研究性创新型PRMT5*MTA抑制剂ABSK131 已完成在MTAP缺失的晚期╱转移性实体瘤患者中的1期临床试验首例患者给药。2025年3月，ABSK131获中国国家药品监督管理局药品审评中心的IND批准。2024年12月，ABSK131获得美国食品药品监督管理局的IND批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072308070897b16216&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072308070897b16216&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1161","03347","BK1574","BK1576","BK1583","BK1515","LU2488822045.USD","09939","02256"],"gpt_icon":0},{"id":"2553139261","title":"丽珠医药抗癫痫1类新药NS-041完成Ⅱ期临床试验首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2553139261","media":"丽珠医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553139261?lang=zh_cn&edition=fundamental","pubTime":"2025-07-23 07:58","pubTimestamp":1753228702,"startTime":"0","endTime":"0","summary":"丽珠医药与纽欧申医药联合宣布，高选择性小分子KCNQ2/3激活剂NS-041已完成Ⅱ期临床试验首例患者给药。NS-041Ⅱ期临床试验采用随机、双盲、安慰剂对照、多中心设计，旨在系统评估NS-041片作为局灶性癫痫添加疗法的有效性、安全性、耐受性及群体药代动力学特征。丽珠医药的信息披露将严格按照法律法规要求，通过指定的信息披露媒体及平台进行发布。丽珠医药对因基于本文内容而做出的任何投资决策所产生的后果，不承担法律责任 。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723080252a6bbe358&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723080252a6bbe358&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01513","BK1141","BK1191","BK1576","03347","BK1583"],"gpt_icon":0},{"id":"2553254281","title":"中证健康产业指数上涨1.03%，前十大权重包含药明康德等","url":"https://stock-news.laohu8.com/highlight/detail?id=2553254281","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553254281?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 22:48","pubTimestamp":1753195683,"startTime":"0","endTime":"0","summary":"金融界7月22日消息，上证指数高开高走，中证健康产业指数 上涨1.03%，报1236.78点，成交额523.15亿元。数据统计显示，中证健康产业指数近一个月上涨6.70%，近三个月上涨7.48%，年至今上涨7.92%。据了解，中证健康产业指数选取医疗保健、食品安全、环保等三大产业中市值最大的100只证券作为指数样本，并以等权重加权。从中证健康产业指数持仓样本的行业来看，医药卫生占比39.12%、主要消费占比30.00%、工业占比24.99%、公用事业占比5.89%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/22224851904091.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02359","LU0052750758.USD","LU2045819591.USD","LU2328871848.SGD","BK1576","LU1997244956.HKD","LU0456842615.SGD","LU2488822045.USD","LU2125910500.SGD","LU0708995583.HKD","LU2242644610.SGD","LU0320764599.SGD","LU1046422090.SGD","603259","LU1997245094.SGD","LU1969619763.USD","LU2495084118.USD","LU1997245177.USD","BK1141","BK1583","BK0216"],"gpt_icon":0},{"id":"2553328230","title":"易方达基金增持泰格医药(03347)37万股 每股作价约49.98港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553328230","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553328230?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 18:56","pubTimestamp":1753181767,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，7月17日，易方达基金增持泰格医药(03347)37万股，每股作价49.9795港元，总金额约为1849.24万港元。增持后最新持股数目为1494.68万股，持股比例为12.14%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1320629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1820825898.SGD","BK0174","BK1141","BK0216","03347","300347","BK1583","BK0077","BK0028","LU1146622755.USD","BK1576"],"gpt_icon":0},{"id":"2553557632","title":"狂砍500亿订单，医药大白马，未来10年无悬念！","url":"https://stock-news.laohu8.com/highlight/detail?id=2553557632","media":"老张投研","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553557632?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 18:38","pubTimestamp":1753180724,"startTime":"0","endTime":"0","summary":"药明康德发布最新业绩预告，公司预计2025年上半年实现净利润约85.61亿元，同比激增101.92%。可见，药明康德业绩端正迎来加速修复。2025年一季报显示，药明康德截止今年3月末，持续经营业务订单高达523.3亿，同比大增47.1%，可谓是手中有粮，心中不慌。5月20日，三生制药把自主研发核心产品独家授予辉瑞，总金额超60亿美元。种种迹象表明，国内创新药的春天，已经到来。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722203959a6baea71&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722203959a6baea71&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0708995583.HKD","LU0052750758.USD","LU1046422090.SGD","BK1574","BK1141","09939","BK1576","BK1583","LU2045819591.USD","LU2242644610.SGD","LU2125910500.SGD","BK1515","BK1161","LU0320764599.SGD","02359","603259"],"gpt_icon":0},{"id":"2553236463","title":"远大医药(00512)：全球创新放射性核素偶联药物TLX591加入国际多中心III期临床试验的申请获中国药监局默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2553236463","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553236463?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 17:07","pubTimestamp":1753175266,"startTime":"0","endTime":"0","summary":"智通财经APP讯，远大医药 发布公告，集团用于治疗前列腺癌的全球创新在研放射性核素偶联药物TLX591加入国际多中心III期临床试验的申请，近日已获得中华人民共和国国家药品监督管理局默示许可，这是集团在核药抗肿瘤诊疗领域的重要研发进展。此外，用于诊断前列腺癌的全球创新RDC产品TLX591-CDx已于2023年8月在中国完成III期临床试验首例患者给药，并于2025年5月完成全部患者入组给药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1320573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","BK4134","III","00512","BK1583","BK1576","03347","BK1141"],"gpt_icon":0},{"id":"2553263842","title":"药明生物五个生产厂通过美国FDA上市批准前检查，商业化预充针灌装厂首获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2553263842","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553263842?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 17:00","pubTimestamp":1753174800,"startTime":"0","endTime":"0","summary":"药明生物商业化预充针灌装生产厂首次通过FDA检查，为向全球客户提供高质量预充针生产解决方案奠定了坚实基础 进一步巩固了药明生物所有生产厂100% PLI通过率的优异质量监管合规记录  无锡2025年7月22日 /美通社/ -- 全球领先的合同研究、开发和生产服务公司药明生物宣布其五个生产厂以零关键发现项和零数据完整性问题，成功通过美国食品药品监督管理局的药品上市批准前检查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4734927_ZH34927_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0516423174.USD","LU2039709279.SGD","BK4195","LU0456846285.SGD","LU0516422366.SGD","BK1610","BK1521","LU0819121731.USD","LU1688375341.USD","SG9999002562.SGD","LU0348825331.USD","LU0326950275.SGD","BK4121","PFS","BK4211","LU0348735423.USD","LU0588546209.SGD","LU1242518857.USD","BK1141","LU0052750758.USD","02269","LU0051755006.USD","LU0823426308.USD","WXXWY","LU0039217434.USD","LU0181495838.USD","LU0516423091.SGD","LU0572944931.SGD","LU0307460666.USD","LU0359201612.USD","LU1794554557.SGD","IE00B0JY6N72.USD","BK1589","LU0979878070.USD","LU1720050803.USD","LU0417516902.SGD","SG9999002463.SGD","LU1880383366.USD","LU0516422440.USD","LU0359202008.SGD","LU0320764599.SGD","LU0043850808.USD","BK1576","LU0456827905.SGD","LU0516422952.EUR","LU1242518931.SGD","LU0823426480.USD","LU0856984785.SGD","LU0327786744.USD","LU0708995583.HKD"],"gpt_icon":0},{"id":"2553334322","title":"药明康德(02359)7月22日斥资2699.38万元回购A股32.32万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2553334322","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553334322?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 16:34","pubTimestamp":1753173248,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药明康德(02359)发布公告，于2025年7月22日斥资2699.38万元(人民币，下同)回购A股股份32.32万股，每股回购价格为82.34-85.73元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1320540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997245177.USD","02359","BK1141","LU2045819591.USD","159982","BK1583","LU0052750758.USD","LU1969619763.USD","BK1576","LU2495084118.USD","399300","LU2488822045.USD","LU2328871848.SGD","603259","LU0320764599.SGD","LU0456842615.SGD","LU2125910500.SGD","LU0708995583.HKD","LU2242644610.SGD","LU1997245094.SGD","LU1046422090.SGD","LU1997244956.HKD","BK0216"],"gpt_icon":0},{"id":"2553223277","title":"每日卖空追踪 | 康龙化成 07月22日卖空量成交21.68万股，卖空比例为2.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553223277","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553223277?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 16:30","pubTimestamp":1753173036,"startTime":"0","endTime":"0","summary":"康龙化成北京时间07月22日，跌2.28%，卖空量成交21.68万股%，较上一交易日增加25.25%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722172504a45bf64d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722172504a45bf64d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03759","BK1576","BK1141"],"gpt_icon":0},{"id":"2553586292","title":"每日卖空追踪 | 泰格医药 07月22日卖空量成交9.95万股，卖空比例为1.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553586292","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553586292?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 16:30","pubTimestamp":1753173035,"startTime":"0","endTime":"0","summary":"泰格医药北京时间07月22日，跌4.45%，卖空量成交9.95万股%，较上一交易日减少55.06%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722172443a6ba75c4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722172443a6ba75c4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1576","BK1141","03347"],"gpt_icon":0},{"id":"2553101239","title":"每日卖空追踪 | 药明康德 07月22日卖空量成交83.47万股，卖空比例为11.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553101239","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553101239?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 16:30","pubTimestamp":1753173031,"startTime":"0","endTime":"0","summary":"药明康德北京时间07月22日，涨0.33%，卖空量成交83.47万股%，较上一交易日减少1.28%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722172331a45bf531&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722172331a45bf531&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU2242644610.SGD","LU1046422090.SGD","BK1141","LU2045819591.USD","LU2125910500.SGD","02359","LU0052750758.USD","BK1576","LU0320764599.SGD","LU0708995583.HKD"],"gpt_icon":0},{"id":"2553282178","title":"湘财证券：ADC到XDC 偶联药物CDMO空间广阔","url":"https://stock-news.laohu8.com/highlight/detail?id=2553282178","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553282178?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 14:31","pubTimestamp":1753165897,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，湘财证券发布研报称，根据弗若斯特沙利文数据，ADC药物外包渗透率显著高于其他生物药领域，催生了中国CDMO市场规模从2018年0.1亿美元跃升至2022年2.1亿美元，预计2030年将达24.5亿美元。全球ADC药物市场的快速崛起以及国内ADC药物蓬勃发展带来的国际认可度的提升将持续推动药企不断加大ADC药物领域的布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1320469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK4139","ADC","CDMO","BK4080","LU0320764599.SGD","LU2125910500.SGD","161027","02359","LU0708995583.HKD","BK1141","LU2242644610.SGD","LU2045819591.USD","LU0052750758.USD","BK1576","BK4231","LU1046422090.SGD"],"gpt_icon":0},{"id":"2553828259","title":"方达控股盘中异动 下午盘大幅上涨5.19%报1.420港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553828259","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553828259?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 14:26","pubTimestamp":1753165595,"startTime":"0","endTime":"0","summary":"2025年07月22日下午盘14时26分，方达控股股票出现波动，股价大幅拉升5.19%。截至发稿，该股报1.420港元/股，成交量9.8万股，换手率0.00%，振幅5.93%。资金方面，该股资金流入10.116万港元，流出2.718万港元。方达控股股票所在的生物技术行业中，整体涨幅为0.96%。其相关个股中，奥星生命科技、北海康成-B、再鼎医药涨幅较大，振幅较大的相关个股有奥星生命科技、北海康成-B、复旦张江，振幅分别为33.33%、26.47%、12.59%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722142635954c6e55&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722142635954c6e55&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","BK1583","01521"],"gpt_icon":0},{"id":"2553284719","title":"昭衍新药盘中异动 下午盘快速跳水5.12%报20.400港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553284719","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553284719?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 14:00","pubTimestamp":1753164035,"startTime":"0","endTime":"0","summary":"2025年07月22日下午盘14时00分，昭衍新药股票出现异动，股价急速下跌5.12%。截至发稿，该股报20.400港元/股，成交量349.741万股，换手率2.94%，振幅8.84%。资金方面，该股资金流入1942.72万港元，流出3468.43万港元。最近的财报数据显示，该股实现营业收入3.11亿港元，净利润4,455.80万港元，每股收益0.0542港元，毛利8,907.85万港元，市盈率191.14倍。昭衍新药股票所在的生物技术行业中，整体涨幅为0.74%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722140035a45b6d62&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722140035a45b6d62&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","06127","BK1141"],"gpt_icon":0},{"id":"2553286759","title":"恒瑞医药宣布重磅减肥创新药 Ⅲ 期临床试验获得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2553286759","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553286759?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 11:24","pubTimestamp":1753154645,"startTime":"0","endTime":"0","summary":"近日，恒瑞医药宣布了一则振奋人心的消息：GLP-1/GIP 双重受体激动剂 HRS9531 注射液治疗中国肥胖或超重受试者的 Ⅲ 期临床试验获得积极顶线结果。这一成果不仅为恒瑞医药在代谢性疾病治疗药物研发领域增添了浓墨重彩的一笔，更为广大肥胖及超重患者带来了新的希望。此次 HRS9531 的 Ⅲ 期临床试验成功，再次彰显了其在医药研发领域的强大实力和创新能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072211262497afe2f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072211262497afe2f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600276","06978","BK1574","03347","BK1161","BK1583","01276","BK1141","BK1191","BK1576"],"gpt_icon":0},{"id":"1140018214","title":"港股异动丨金斯瑞生物科技涨超8%，预计上半年扭亏为盈最多录得逾2亿美元利润","url":"https://stock-news.laohu8.com/highlight/detail?id=1140018214","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140018214?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 10:04","pubTimestamp":1753149889,"startTime":"0","endTime":"0","summary":"7月22日，$金斯瑞生物科技(01548)$盘初涨超8%，预计上半年扭亏为盈最多录得逾2亿美元利润。消息面上，公司公告，截至2025年6月30日止六个月，集团预计除税前利润较上期显著增加，其中不包括报告期内应占传奇生物科技股份有限公司的损益；及因传奇于2024年10月18日从集团解除合并带来的上期已终止经营业务亏损。经调整，集团预计报告期内录得约1.754亿美元至2.046亿美元的除税前利润，而集团上期的除税前亏损约为1.279亿美元。","market":"us","thumbnail":"https://static.tigerbbs.com/1fc1f5e2fa377c378fa230c10e0849a2","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/1fc1f5e2fa377c378fa230c10e0849a2"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","HK0000320223.HKD","HK0000306685.HKD","01548","BK1576","BK4614","HK0000320264.USD","BK1141","HK0000306701.USD"],"gpt_icon":0},{"id":"2553004288","title":"【港股医药股多数走强 博安生物涨超8%】截至发稿，博安生物(06955.HK)涨8.33%、金斯瑞生物科技(01548.HK)涨7.19%、再鼎医药(09688.HK)涨6.76%、来凯生物-B(02105.HK)涨5.57%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2553004288","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553004288?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 09:57","pubTimestamp":1753149444,"startTime":"0","endTime":"0","summary":"截至发稿，博安生物(06955.HK)涨8.33%、金斯瑞生物科技(01548.HK)涨7.19%、再鼎医药(09688.HK)涨6.76%、来凯生物-B(02105.HK)涨5.57%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/22095751870107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","02105","BK4548","HK0000320223.HKD","BK4139","HK0000306701.USD","HK0000306685.HKD","ZLAB","BK1574","BK1576","159718","BK1161","BK4585","BK4588","BK4531","LU2488822045.USD","09688","01548","BK1583","HK0000320264.USD","BK1588","BK4526","06955"],"gpt_icon":0},{"id":"2553121283","title":"口服多肽向FDA递交上市申请 药明康德共同强生等参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2553121283","media":"银柿财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553121283?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 09:49","pubTimestamp":1753148950,"startTime":"0","endTime":"0","summary":"据药明康德官微7月22日消息，药明康德共同强生与Protagonist Therapeutics今日宣布，已向美国FDA提交新药申请，寻求批准其在研、每日一次口服多肽疗法icotrokinra上市，用于治疗12岁及以上中度至重度斑块状银屑病成人与儿科患者。Icotrokinra在上述3期研究中成功达成所有主要终点与共同主要终点，在12岁及以上中度至重度斑块状银屑病成人与儿科患者中，显示出显著的皮肤症状清除效果和良好的安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722095441a6b9730a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722095441a6b9730a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU0320764599.SGD","LU0708995583.HKD","LU2242644610.SGD","02359","BK1141","LU0052750758.USD","LU2045819591.USD","LU2125910500.SGD","BK1576","LU1046422090.SGD"],"gpt_icon":0},{"id":"1129671476","title":"港股异动 | 丽珠医药涨超9%，LZM012 Ⅲ期临床试验达主要研究终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1129671476","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129671476?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 09:42","pubTimestamp":1753148532,"startTime":"0","endTime":"0","summary":"7月22日，$丽珠医药$盘初涨超9%，消息面上，丽珠医药公布，近日，该公司控股附属公司珠海市丽珠单抗$生物$技术有限公司与北京鑫康合生物医药科技有限公司联合开发的“重组抗人IL-17A/F人源化单克隆抗体注射液”的Ⅲ期临床试验达到主要研究终点。第12周PASI 100应答率，LZM012为49.5%，对照组司库奇尤单抗为40.2%，显示出LZM012 非劣效于司库奇尤单抗且优效于司库奇尤单抗。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1320369.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1576","BK4614","BK1191","BK1583","01513","BK1141"],"gpt_icon":0},{"id":"2553128874","title":"金斯瑞生物科技盘中异动 早盘急速上涨5.12%报17.260港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553128874","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553128874?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 09:42","pubTimestamp":1753148529,"startTime":"0","endTime":"0","summary":"2025年07月22日早盘09时42分，金斯瑞生物科技股票出现波动，股价大幅上涨5.12%。截至发稿，该股报17.260港元/股，成交量702.27万股，换手率0.32%，振幅2.80%。资金方面，该股资金流入6310.22万港元，流出3152.38万港元。金斯瑞生物科技股票所在的生物技术行业中，整体涨幅为0.06%。金斯瑞生物科技公司简介：金斯瑞生物科技股份有限公司是一家主要从事生物科学研究及相关业务的香港投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722094209a6b96d2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722094209a6b96d2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306685.HKD","01548","HK0000306701.USD","HK0000320223.HKD","BK1141","BK1583","BK1576","HK0000320264.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":187,"code":"91000000","status":"200"}]}}